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Insulin receptor substrate-1 (IRS1) is a well-
characterised intracellular substrate for insulin 
receptor tyrosine kinases containing Src homology 
2 (SH2) domains, e.g. phosphatidylinositol 3-kinase, 
growth factor receptor-bound protein 2 and SH2-
containing protein tyrosine phosphatase in the insulin-signalling 
cascade.[1] Extensive studies on several amino-acid variations of 
the IRS1 gene have shown associations with human metabolic 
disorders such as type 2 diabetes mellitus (T2DM),[2] obesity[3] 
and insulin resistance in various population studies as well as in 
animal models. [4] Gly972Arg (rs1801278) is the most studied single-
nucleotide polymorphism (SNP) of the IRS1 gene because it is a 
functional mutant reported to impair insulin signalling in transfected 
cell lines and in human cells carrying the variant.[5-7] There are no data 
currently available for populations in Africa. 
Therefore, our study objective was to determine the frequency 
of Gly972Arg and investigate its associations with T2DM, insulin 
resistance and obesity traits in the mixed-ancestry population of 
South Africa (SA), which has been found previously to be prone to 
diabetes.[8] 
Methods
Study setting and population
The study setting, survey design and procedures have been described 
in detail elsewhere.[8,9] Briefly, eligible participants were invited to 
take part in a community-based survey from January 2008 to March 
2009 (cohort 1), and January to November 2011 (cohort 2) in Bellville 
South, Cape Town, SA. The study was approved by the research ethics 
committees of Stellenbosch University and the Faculty of Health and 
Wellness Sciences, Cape Peninsula University of Technology. All 
participants gave written informed consent after all the procedures 
were fully explained in the language of their choice.
Clinical data
All consenting participants received a standardised interview and 
physical examination during which blood pressure (BP) was measured 
according to the World Health Organization (WHO) guidelines[10] 
using a semi-automated digital BP monitor (Rossmax, USA) on 
the right arm in a sitting position. Other clinical measurements 
included body weight, height, and waist and hip circumferences. 
All anthropometric measurements were performed three times and 
results averaged. Participants with no history of doctor-diagnosed 
diabetes underwent a 75 g oral glucose tolerance test (OGTT) as 
recommended by the WHO.[11]
Laboratory measurements
Blood samples were collected after an overnight fast and processed 
for further biochemical analysis. Plasma glucose was measured 
using the enzymatic hexokinase method, and glycated haemoglobin 
(HbA1c) by turbidimetric inhibition immunoassay (Cobas 6000, 
Roche Diagnostics, Germany). Total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), and triglycerides (TGs) 
Background. The most common single-nucleotide polymorphism in the insulin receptor substrate-1 (IRS1) gene is Gly972Arg, which is 
associated with a 25% increased risk of developing diabetes. The mixed-ancestry population of South Africa (SA) has one of the highest 
prevalences of type 2 diabetes mellitus (T2DM) in Africa.
Objective. To report the frequency of IRS1 Gly972Arg and investigate its associations with cardiometabolic traits.
Methods. DNA from 856 mixed-ancestry adults drawn from an urban community of Bellville South, Cape Town, SA, was genotyped by two 
independent laboratories. Oral glucose tolerance tests were performed and cardiometabolic risk factors measured. 
Results. A total of 237 (24.7%) participants had T2DM. The IRS1 Gly972Arg variant was present in 7.9% of the individuals studied and only 
one participant (non-diabetic) carried the homozygous A/A variant. In linear and logistic regression analyses, Gly972Arg was not associated 
with obesity, insulin resistance/sensitivity or T2DM.
Conclusions. The prevalence of the Gly972Arg variant in the mixed-ancestry population of SA is comparable to that reported in African 
Americans, but its presence is not associated with cardiometabolic traits. This suggests that the Gly972Arg variant may not aid diabetes 
risk evaluation in this setting, nor can such information help explain the high prevalence of diabetes previously reported in this population.
S Afr Med J 2014;104(6):420-423. DOI:10.7196/SAMJ.7419
No evidence for association of insulin receptor substrate-1 
Gly972Arg variant with type 2 diabetes mellitus in 
a mixed-ancestry population of South Africa 
Z Vergotine,1,2 MSc; A P Kengne,3 MD, PhD; R T Erasmus,2 FCPath; T E Matsha,1 PhD
1  Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Cape Town, South Africa
2  Division of Chemical Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa
3  National Collaborative Research Programme for Cardiovascular and Metabolic Diseases, South African Medical Research Council, Tygerberg and 
University of Cape Town, South Africa
Corresponding author: T E Matsha (matshat@cput.ac.za)
RESEARCH
421       June 2014, Vol. 104, No. 6
were estimated by enzymatic colorimetric methods (Cobas 6000, 
Roche Diagnostics, Germany). Low-density lipoprotein cholesterol 
(LDL-C) was calculated using Friedewald’s formula.[12] Insulin was 
determined using a microparticle enzyme immunoassay (Axsym, 
Abbott, USA). 
SNP genotyping
Genomic DNA was extracted from whole-blood samples collected in an 
EDTA tube. For quality control purposes, genotyping for IRS1 Gly972Arg 
(rs1801278) was carried out in two independent laboratories on the ABI 
Prism 7900HT platform (Applied Biosystems, USA) and a BioRad Optica 
(BioRad, USA) using Taqman genotyping assay (Applied Biosystems, 
USA). In all but two cases, there was complete agreement concerning the 
genotypes. Consensus agreement was achieved by the comparisons of raw 
data outputs and automated sequencing using ABI 3730. 
Definitions
Body mass index (BMI) was calculated as weight (in kg)/m2 and 
waist-to-hip ratio as waist/hip circumferences (in cm). Diabetes 
status was based on a history of doctor diagnosis, a fasting plasma 
glucose ≥7.0 mmol/l and/or a 2-hour post-OGTT plasma glucose 
≥11.1 mmol/l. The following calculations were used:
• homeostatic model assessment of insulin resistance (HOMA-IR) 
= [fasting insulin concentration (µIU/l) × fasting plasma glucose 
(mmol/l)] ÷ 22.5 
• functional β-cells (HOMA-β%) = [20 × fasting insulin (μIU/ml)] ÷ 
[fasting glucose (mmol/ml) − 3.5]
• fasting insulin resistance index (FIRI) = [fasting insulin (μU/ml) × 
fasting glucose (mM)] ÷ 25
• quantitative insulin-sensitivity check index (QUICKI) = 1 ÷ 
[log(fasting insulin (μU/ml) × log(fasting glucose (mg/dl))][13] 
Statistical analyses
Of the 1 256 participants who took part in the survey, 1 035 
consented to genetic studies. Among the latter, 126 were excluded 
because they were related to the other participants, and 53 were 
excluded owing to missing data on the genetic or T2DM trait 
variables. Therefore, 856 had valid data for the current analyses. 
General characteristics of the study group were summarised as n and 
% for dichotomous traits, and mean ± standard deviations (SDs) or 
median and 25th - 75th percentiles for quantitative traits. Traits were 
log-transformed to approximate normality, where necessary, prior 
to analysis. SNPs were tested for departure from Hardy-Weinberg 
Equilibrium (HWE) via a χ2 goodness-of-fit test. Linear regression 
Table 1. General characteristics of the overall population by diabetic status
Overall No diabetes Diabetes p-value
Patients, n 856 619 237
Gender (male), n 235 51 184 0.83
Age (years), mean (±SD) 53.4 (±15.4) 51.0 (±15.5) 50.6 (±13.5) <0.0001
Clinical, mean (±SD)
Systolic BP (mmHg) 125 (±21) 123 (±19) 130 (±23) <0.0001
Diastolic BP (mmHg) 76 (±13) 75 (±12) 77 (±15) 0.07
BMI (kg/m2) 29.9 (±7.2) 29.3 (±7.1) 31.7 (±7.1) <0.0001
Waist circumference (cm) 96 (±15) 95 (±15) 102 (±14) <0.0001
Hip circumference (cm) 109 (±14) 109 (±14) 111 (±15) 0.04
Waist-to-hip ratio 0.88 (±0.10) 0.87 (±0.10) 0.92 (±0.08) <0.0001
Laboratory
HbA1c (%), mean (±SD) 6.3 (±1.5) 5.7 (±0.4) 7.8 (±2.1) <0.0001
HbA1c (mmol/mol) (±SD) 45.4 (±16.4) 38.8 (±4.4) 61.7 (±23.0) <0.0001
Fasting blood glucose (mmol/l), mean (±SD) 6.4 (±3.1) 5.1 (±0.7) 9.6 (±4.3) <0.0001
2-hour plasma glucose (mmol/l), mean (±SD) 7.5 (±3.6) 6.4 (±1.6) 13.4 (±5.3) <0.0001
TG (mmol/l), mean (±SD) 1.5 (±0.9) 1.4 (±0.9) 1.7 (±0.9) <0.0001
HDL-C (mmol/l), mean (±SD) 1.3 (±0.4) 1.3 (±0.4) 1.2 (±0.3) <0.0001
LDL-C (mmol/l), mean (±SD) 3.6 (±1.0) 3.6 (±1.0) 3.7 (±1.1) 0.14
TC, mean (±SD) 5.6 (±1.2) 5.5 (±1.2) 5.7 (±1.3) 0.06
Insulin, median (25 - 75th percentile) 7.5 (3.4 - 13.8) 6.9 (3.3 - 12.5) 10.2 (4.4 - 17.6) <0.0001
2-hour insulin, median (25 - 75th percentile) 37.1 (19.5 - 73.0) 35.1 (19.2 - 63.5) 62.3 (24.3 - 118.7) <0.0001
Glucose/insulin, median (25 - 75th percentile) 0.74 (0.42 - 1.63) 0.72 (0.41 - 1.51) 0.78 (0.47 - 2.05) 0.10
HOMA-IR, median (25 - 75th percentile) 1.9 (0.8 - 3.8) 1.6 (0.7 - 2.9) 3.6 (1.6 - 7.3) <0.0001
HOMA-β (%), median (25 - 75th percentile) 72.7 (30.9 - 146.5) 90 (41.8 - 162) 44.5 (13.5 - 81.7) <0.0001
QUICKI, median (25 - 75th percentile) 0.15 (0.14 - 0.17) 0.15 (0.14 - 0.18) 0.14 (0.12 - 0.15) <0.0001
FIRI, median (25 - 75th percentile) 1.69 (0.75 - 3.39) 1.4 (0.6 - 2.6) 3.2 (1.4 - 6.6) <0.0001
1/HOMA-IR, median (25 - 75th percentile) 0.53 (0.26 - 1.20) 0.64 (0.34 - 1.49) 0.28 (0.14 - 0.63) <0.0001
SD = standard deviation; BP = blood pressure; BMI = body mass index; HbA1c = glycated haemoglobin; TG = triglyceride; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density 
lipoprotein cholesterol; TC = total cholesterol; HOMA-IR = homeostatic model assessment of insulin resistance; HOMA-β = functional β-cells; QUICKI = quantitative insulin-sensitivity check 
index; FIRI = fasting insulin resistance index. 
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models were used for the analysis of quantitative traits and logistic 
regression models for dichotomous traits, always assuming additive 
models for the SNPs. We investigated the additive allelic association 
of Gly972Arg with each trait, overall and according to diabetes 
status, and tested for heterogeneity by adding the interaction term of 
diabetes and Gly972Arg to a model that contained the main effects of 
diabetes and Gly972Arg. A p-value <0.05 was considered significant. 
We did not adjust for multiple testing. All analyses were done with R 
(version 2.12.2).
Power calculation
Power calculation was performed with CaTS,[14] assuming a diabetes 
prevalence of 28%,[8] a Gly972Arg frequency of 19%,[2] a genotype 
odds ratio of 1.25[15] under an additive model and a nominal p-value 
of <0.05. Based on the above, our population of 224 diabetic and 619 
non-diabetic patients provided a statistical power of 60% for a one-
stage design.
Results
Clinical characteristics of participants according to diabetes status 
are summarised in Table 1; 237 (24.7%) participants had T2DM. 
Compared with non-diabetic participants, those with diabetes had 
significantly higher adipometric variables (all p≤0.04), systolic 
BP (p<0.0001) and TGs (p<0.0001), whereas HDL-C levels were 
significantly lower (p<0.0001). 
Gly972Arg demonstrated HWE (p>0.05) according to gender 
and diabetes status. No significant differences in the genotype 
and allele distributions were observed between the study groups. 
The frequency distributions, both genotype and allele, did not 
differ significantly according to diabetes status or gender. The 
prevalence rate for the heterozygous variant (G>A, rs1801278) 
was 7.9% (n=68) overall, 6.7% (n=16) in diabetic and 8.4% (n=52) 
in non-diabetic participants. Only one participant (non-diabetic) 
carried the homozygous variant (A/A) with a corresponding A allele 
frequency of 4.1% overall, 3.4% in diabetic and 4.4% in non-diabetic 
participants. In linear regression analyses, IRS1 Gly972Arg was 
associated with none of the markers of glycaemia, insulin resistance 
or insulin sensitivity, both overall and in participants with and 
without diabetes taken separately, with no evidence of significant 
statistical interaction by diabetes status (all interaction p≥0.30), 
except for 2-hour glucose measurements where the effect size 
appeared to be greater among diabetic v. non-diabetic participants 
(interaction p=0.19) (Table 2). In logistic regression analyses, 
IRS1 Gly972Arg was not associated with prevalent diabetes after 
adjustment for age and sex, and after further adjustment for markers 
of insulin resistance/sensitivity, and markers of adiposity. 
Discussion
Our study investigated the frequency of the IRS1 Gly972Arg variant 
in the mixed-ancestry population of SA. The overall prevalence of 
IRS1 Gly972Arg was 7.9%, with a higher occurrence of the variant 
found in non-diabetics, and it was not associated with obesity, insulin 
resistance/sensitivity or T2DM. This suggests that knowledge of the 
the Gly972Arg variant status may not aid diabetes risk evaluation in 
this setting, and that it cannot explain the high prevalence of diabetes 
previously reported in this population.
Epidemiological studies on the association between the IRS1 
Gly972Arg (rs1801278) SNP and various cardiometabolic traits have 
reported conflicting results.[2,3,15-19] Although individuals carrying the 
Gly972Arg SNP have a 25% increased risk of developing diabetes,[15] 
genome-wide association studies involving subjects of European 
descent found no association between IRS1 and T2DM.[16,17] Instead, 
a genetic variant, rs294361, located near IRS1 was associated with 
T2DM in a large-scale study of French and Danish individuals.[17] 
Similarly, these associations have not been found[18] in populations 
with a high prevalence of diabetes such as ours[8] and Pima Indians. [20] 
Jellema et al.[15] investigated some of these factors, including ethnicity, 
type of study, diagnostic test used to confirm the presence of 
diabetes, type of measurement of the polymorphism, prevalence of 
the polymorphism and age. These authors reported heterogeneity for 
type of study, diagnostic test used to exclude diabetes in the control 
subjects, and age of the case subjects as sources of inconsistency 
across studies.[15] 
The majority of the studies, including ours, used population-
based designs that did not account for the gene-gene interaction 
phenomenon, defined as an interaction in which one gene 
suppresses or enhances the expression of another. For example, 
the protective effect against insulin resistance of the Ala allele 
Pro12Ala polymorphism in the peroxisome proliferator-activated 
receptor gamma 2 (PPARγ2) gene was shown to be enhanced in the 
Table 2. Generalised linear regression model of the phenotypic features for the at-risk allele A*
Phenotype
Overall No diabetes Diabetes
Interaction 
(p-value)
Effects size  
(95% CI) p-value
Effects size  
(95% CI) p-value
Effects size  
(95% CI) p-value
Fasting glucose 0.05 (-0.56 - 0.62) 0.86 0.12 (-0.07 - 0.32) 0.21 -0.16 (-2.32 - 2.00) 0.88 0.67
2-hour glucose 0.36 (-0.28 - 1.01) 0.27 0.06 (-0.35 - 0.48) 0.77 2.56 (-1.26 - 6.38) 0.19 0.01
HbA1c 0.01 (-0.27 - 0.28) 0.95 0.02 (-0.09 - 0.13) 0.73 -0.02 (-1.09 - 1.03) 0.96 0.88
Fasting insulin -0.06 (-4.35 - 4.22) 0.98 -0.34 (-2.87 - 2.18) 0.79 0.64 (-14.63 - 15.92) 0.93 0.82
2-hour insulin 5.73 (-11.05 - 22.51) 0.50 2.20 (-14.54 - 18.94) 0.80 23.03 (-33.94 - 80.01) 0.43 0.30
Glucose/insulin -0.36 (-2.76 - 2.05) 0.77 -0.33 (-2.35 - 1.68) 0.75 -0.30 (-7.78 - 7.18) 0.94 >0.99
HOMA-IR 0.03 (-1.77 - 1.84) 0.97 -0.04 (-0.64 - 0.56) 0.89 0.12 (-6.81 - 7.05) 0.97 0.91
QUICKI -0.002 (-0.01 - 0.01) 0.70 -0.001 (-0.02 - 0.01) 0.88 -0.006 (-0.03 - 0.01) 0.54 0.73
FIRI 0.03 (-1.59 - 1.65) 0.97 -0.04 (-0.58 - 0.50) 0.89 0.11 (-6.13 - 6.35) 0.97 0.91
CI = confidence interval; HbA1c = glycated haemoglobin; HOMA-IR = homeostatic model assessment of insulin resistance; HOMA-β = functional β-cells; QUICKI = quantitative insulin-sensitivity 
check index; FIRI = fasting insulin resistance index.
*Models are adjusted for age, sex and presence of diabetes.
RESEARCH
423       June 2014, Vol. 104, No. 6
presence of the IRS1 Gly972Arg variant.[21] Insulin sensitivity was 
significantly greater in X/Ala (PPARγ2) + X/Arg (IRS1 Gly972Arg) 
than in Pro/Pro (PPARγ2) + X/Arg (IRS1 Gly972Arg) carriers.[21] 
Furthermore, a study that investigated the development of diabetes 
in mice with three mutations in the insulin receptor, IRS1 and IRS2 
reported a higher prevalence (40%) of progression to diabetes in 
mice with all three mutations compared with mice carrying one 
mutation (5%).[22] 
Study strengths
Our study included extensive data collection on a range of diabetes 
determinants, and is the first study to investigate the IRS1 Gly972Arg 
variant in an African population using two independent laboratories 
to genotype our study population. 
Study limitations
The study was limited by the cross-sectional design. The sample 
size was small, so therefore replication of this analysis in a larger 
sample size is required to definitively rule out the association 
between IRS1 Gly972Arg and diabetes. We did not adjust for 
population stratification, as appropriate markers that can be used 
to map disease genes or correct for population stratification in the 
mixed-ancestry population are not yet available. Potential population 
stratification in unrelated samples may cause spurious positive or 
negative associations in population-based association studies.[23] 
Insulin resistance was not based on the glycaemic clamp.
Conclusion
The prevalence of the Gly972Arg variant in the mixed-ancestry 
population of SA is comparable to that in African Americans 
(11.6% in control subjects),[24] but was not associated with obesity, 
insulin resistance/sensitivity or diabetes. The lack of association 
found between the IRS1 Gly972Arg variant and diabetes in this 
population study does not exclude its role in the gene-gene and gene-
environment interaction mechanisms underlying the pathogenesis 
of diabetes. 
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